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Abstract 
The current role of economic appraisal in health policy and medical practice is outlined, 
emphasizing the pharmaceutical sector where developments are most marked. General health 
policy in the Netherlands and pharmaceutical policy in Australia are presented as examples 
of how economic appraisal may diffuse further as a decision-support tool for health 
authorities. This can be promoted by studying how policy-makers interpret and use results 
of economic evaluation studies and how the international transferability of information on 
the cost-effectiveness profiles of health technologies can be enhanced. To be relevant for 
health policy, results from economic appraisal studies must be valid and reliable, relevant to 
the policy context and communicated to the proper decision-makers. A number of recom- 
mendations are provided for economic appraisals to meet such requirements. 
Keywords: Economic evaluation; Health care decision making; Policy impact 
1. Introduction 
The objective of this paper is to describe the current role of economic appraisal 
in health policy and medical practice. The various ways to control the diffusion of 
medical technologies are considered, as well as the reliance on economic appraisal 
in these options for regulatory control. General health policy in the Netherlands 
and pharmaceutical policy in Australia are presented as examples where economic 
appraisal has diffused further as a decision supporting tool. Economic evaluation or 
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economic appraisal is understood here as all scientific studies aimed at describing or 
predicting the differential costs and benefits of two or more alternative interven- 
tions, which are open to a policy maker. Specific problems with the use of 
cost-effectiveness information in health policy are discussed, such as the use of 
cost-effectiveness profiles based on prospective clinical trials and the need to 
extrapolate from such information. Finally, some tentative observations will be 
made on the future development of economic appraisal as a tool for health policy. 
2. Economic appraisal in support of various policy instruments 
When considering the options for controlling the diffusion of health care tech- 
nologies, one may usefully distinguish between regulation by directive and regula- 
tion by incentive [l]. The former can be seen as a direct way of interfering with 
resource allocation, while the latter concerns policies influencing the diffusion of 
technologies and treatments in an indirect way. Table 1 provides an overview of 
possible regulatory mechanisms, some of which may be supported by economic 
appraisal. The type of health care system, government dominated or more Iiberal, 
determines the relevant mix of policy instruments. Below we will consider a number 
of these control mechanisms and assess the role of economic appraisal in the use of 
such instrument. 
2.1. Excluding technologies from public reimbursement 
Economic appraisal is beginning to play a role in deciding on the exclusion or 
inclusion of medical technologies from public reimbursement. One of the first 
well-known approaches in the U.S. was the so-called ‘Oregon-plan’ to ration the 
health insurance package of the state Oregon on the basis of global information on 
costs and benefits of various facilities. This information, based on consensus 
procedures and the opinion of population-panels and experts, supported the 
exclusion of some benefits from the package as from early 1994 onwards. An 
Table 1 
Options for control of the diffusion of health care technologies 
Regulation by directive Regulation by incentive (central/regional government) 
Pre-market controls for drugs and devices Reforming payment schemes for health care institutions 
(e.g. hospitals) 
(Conditional) exclusion from public 
reimbursement 
Budgetary reform within institutions 
Planning of specialist facilities or specific Changing payment systems for health care providers 
technologies 
Cost-sharing arrangements 
Encouraging competition in the health care system 
Source: adapted from Rutten and Haan [l]. 
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evaluation study of the Oregon approach is in progress. Also with regard to the 
Medicare package, early studies on the most cost-effective strategy to treat end- 
stage-renal disease and the role of EPO (erythropoietin) in the support of dialysis 
patients have been influential in policy decisions [2]. 
A systematic approach can be found in the Netherlands, where the Health 
Insurance Executive Board consistently uses economic appraisal to support deci- 
sions on the health insurance package. In 1986 this Board decided to adopt a 
three-step procedure for deciding on major additions to the health insurance 
benefit package: diffusion of the new technology should be limited and controlled, 
a medical technology assessment should be carried out simultaneously, and finally, 
a decision should be made on the basis of such study. A number of large medical 
technology assessments (MTAs) have been carried out under this program, nota- 
bly all new transplant studies such as heart, liver and lung transplantation. The 
results have been quite influential in deciding on inclusion in the benefit package 
[31. 
In 1988, the so-called Investigative Medicine Fund was initiated, which is now 
the main source of finance for health care technology assessment in the Nether- 
lands, and potentially well placed to assure policy relevance and ultimate impact 
on practice. This Fund exists of 36 million guilders a year, and is intended to 
support projects to evaluate new or established medical technologies, looking 
prospectively at cost-effectiveness and sometimes also social, ethical and legal 
implications in view of the policy decisions to be taken. Proposals are submitted 
by university hospitals and approved on by a special committee on the Investiga- 
tive Medicine Fund at the Health Insurance Executive Board. Since 1988, 80 
projects have been funded and 15 projects are finished and have submitted final 
reports. Most of the finished studies produced recommendations for clinical pro- 
tocols, a number led to a conclusion regarding the composition of the benefit 
package and one was related to a licensing procedure for a specialist facility. 
Critical remarks on this program relate to the fact that, although the bottom-up 
procedure taps the creativity and interest of the medical scientific community, 
many of the projects could not be considered high priority in terms of solving the 
problems faced in health policy. Therefore, plans have been made to combine the 
top-down and bottom-up approach in the Investigative Medicine Fund and to 
initiate an exercise to set priorities for MTA-research. One of the consequences of 
the program has been that medical technology assessment as an interdisciplinary 
effort develops well in the Netherlands and meets increasing interest from clini- 
cians and policy-makers. 
In conclusion, there is some evidence that economic appraisal supports deci- 
sions on inclusion or exclusion of general medical technologies from the benefit 
package. Dutch experience has learned that for such information to be useful in 
policy-making, a continuous dialogue between policy-makers and researchers is 
required, especially in the design phase. Furthermore, the identification of medical 
technologies to be submitted to an MTA is considered difficult but necessary to 
increase the impact of economic appraisal on policy-making. 
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2.2. Pricing and reimbursement of medicines 
The role of economic appraisal is more prominent in policies on pharmaceuticals, 
especially in those regarding reimbursement. In many countries, especially the U.S. 
and some European countries, the increase in expenditure on pharmaceutical care 
has been significantly larger than the increase in total health care expenditure for a 
number of years now. Different policies to contain the costs of pharmaceutical care 
reflect the degree of government control on the sector and suggest little consensus 
among policy-makers on how to tackle this problem. In a number of countries like 
Belgium, Switzerland, France and Italy, the prices of medicines are set by the 
government, but only in the latter two cases is there some consideration of prices 
relative to therapeutic value, and in France a favourable cost-effectiveness profile 
may help the industry to negotiate a good price for a product. 
How economic appraisal may support direct price regulation is not an easy 
question. There are obviously at least two issues: that of a just price in terms of a 
fair award to the (risk bearing) industry and that of an acceptable price in terms of 
a reasonable cost-effectiveness level relative to the competitive drug as seen from a 
societal perspective. Economic appraisal has no contribution to assessing the 
fairness of a price. And only if an implicit or explicit cut-off point for cost-effective- 
ness is chosen [4], does it provide something to hold on to for determining an 
acceptable price. Sometimes this distinction between equity- and efficiency-consider- 
ations is blurred and economic appraisal is misused to defend or justify a price. 
Reimbursement of pharmaceuticals on the basis of some social security arrange- 
ment (from insurance premiums to taxes) may be restricted in many different ways 
and economic studies may be useful in all these cases. There may be positive or 
negative lists of pharmaceuticals eligible for reimbursement, there may be restric- 
tions on reimbursement (e.g. specific indication groups, a priori approval by 
controlling physicians), or one may require mandatory returns on products reim- 
bursed by the social security system (e.g. Belgium). Regarding reimbursement of 
pharmaceuticals there are two interesting new developments: the establishment of a 
formal role for economic analysis in decision-making in Australia and Canada and 
the introduction of reference price systems in Germany, the Netherlands, Denmark, 
Sweden and Norway. The first development is illustrated with the example of 
Australia, where since January 1993 economic appraisal is legally required for the 
pharmaceutical industry in Australia when submitting their products for listing on 
the Pharmaceutical Benefits Scheme. Only if a drug is listed on this scheme, will its 
use be subsidized by the Commonwealth Government. By the end of 1994, 133 
submission for listing were filed, nearly half of which could be characterized as 
cost-effectiveness analyses, the other two quarters being either cost-minimization 
analyses or incomplete, qualitative analyses. Mitchell [5] from the Pharmaceutical 
Evaluation Section of the Commonwealth Department stresses the pivotal place of 
the measurement of clinical performance and reports very few cases where an 
economic difference could be substantiated without being able to demonstrate a 
clinical difference. Furthermore, he emphasises a hierarchy for preferred primary 
evidence for economic evaluation, defined as: 
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1. randomised head to head trials; 
2. transitive analysis of randomised head to head trials; 
3. observational studies; 
4. expert opinion. 
Finally, he thinks it is necessary to define more explicitly the role of modelling. 
Further clarification of all these points is sought in the draft guidelines 1995. 
Under reference pricing no prior judgement is made about which drugs will be 
reimbursed. In this system a price is set at which a given category or class of drugs 
will be reimbursed. A patient buying a particular drug is reimbursed up to the 
reimbursement limit, determined for the associated cluster. If the drug is priced 
above this reimbursement limit, the patient pays the difference out of pocket. Such 
a system may be appealing to policy-makers, who see a way to encourage price 
competition by industry, but the reported effects to date have been small [6]. In the 
Netherlands, for instance, where there has been a price reference system since July 
1991, the government does not seem to be satisfied by its accomplishments as it is 
now considering direct price regulation as an additional cost-containment measure. 
In principle, these price reference systems may be appealing to economists, who 
argue that costs and effects per drug within a cluster of drugs are equal, at least 
from the perspective of the third payer. This would be in line with a cost-effective- 
ness perspective, but the practice of these systems suggests otherwise. First, there 
are problems with the clustering of drugs on the basis of equal effectiveness, 
especially in case generic products and specialities are clustered together. Such a 
dispute has arisen in the Dutch case, where an original product (sumatriptan) and 
a generic product (ergotamine) were clustered together [7]. A further problem is 
that effectiveness, and indeed cost-effectiveness may differ with the indication. For 
example, HMG-CoA reductase inhibitors like pravastatin and simvastatin show 
different cost-effectiveness in preventing cardiovascular disease related to, for 
instance, initial cholesterol levels. Other problems occur when new indications for 
a particular product emerge, e.g. in the case of ACE-inhibitors, which are now also 
indicated for patients after acute myocardial infarction. In general, price reference 
systems do not take into account that cost-effectiveness is not a characteristic of a 
pharmaceutical product per se, but rather of the process of prescribing the drug to 
specific patients. Also on the cost side there may be different profiles for drugs 
within one cluster, despite the equal reimbursement costs to the third party payer. 
The latter does not take into account that medication may impact the duration of 
treatment differently, or that medication may have different effects on the overall 
use of health care resources. Furthermore, in all countries the determination of the 
level of the reimbursement limit is historically based. No evidence on the balance of 
societal costs versus benefits for a particular drug or group of drugs is being 
considered. The cost-effectiveness level which can be associated with each cluster of 
drugs, may also differ across the various clusters. A situation may occur where a 
cost-effective drug in one cluster may be reimbursed at a lower rate than a less 
cost-effective drug from another cluster. And finally, price referencing introduces 
cost sharing and may therefore have unfavourable equity implications. In particu- 
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lar, chronic patients, who take medication daily and who for some reason cannot 
switch to another medication, may experience significant increases in out of pocket 
payment. As economic evaluation is the only approach available to identify and 
compare the costs and consequences of health care interventions, we conclude that 
price reference systems are not an alternative to the use of economic appraisal in 
reimbursement decisions. The latter may be used as a complementary source of 
information, for instance to support the determination of reimbursement limits, 
both within clusters and across clusters. 
In summary, with respect to pricing and reimbursement of medicines, we observe 
a growing role of economic appraisal in these decisions. Efforts are made to define 
even more clearly what information is needed for policy decisions and this may help 
to increase the quality and consequent impact of future economic studies. Reference 
pricing is clearly not an alternative to the use of economic appraisal, but may 
benefit from using cost-effectiveness information to support the determination of 
reimbursement limits. 
2.3. Planning of specialist facilities or specljic technologies 
A second mechanism to control the diffusion of medical technologies is the 
planning of specialist facilities or specific technologies. Public health authorities 
may want to regulate such diffusion, because certain facilities may show ‘economies 
of scale’ or should only be provided under strict conditions regarding quality of 
care or otherwise. There is surprisingly little work to support such decision-making, 
although some countries exercise a sort of licensing procedure for advanced medical 
facilities. For instance, the Netherlands has a licensing option for particular 
specialist facilities in the context of article 18 of the Hospital Facilities Act. 
Although a budget has even been made available for research to support decision- 
making under this regimen, no work can be reported yet. Recently, the Health Care 
Financing Administration in the U.S. has initiated a study on economies of scale in 
open-heart surgery and in the UK, the heart transplant study performed during in 
mid-80s also considered the economic effects of further diffusion across more than 
the two units performing transplants at that time [B]. 
As a conclusion, we observe that there is a wide, almost unexplored, field open 
for economic research to support the planning of specialist facilities. 
2.4. Regulation by incentive 
Regulation by incentive requires that appropriate incentive structures are in place 
for the key actors in the health care system. Such incentives should stimulate them 
to act efficiently from a societal perspective. This means that reimbursement 
schemes, cost-sharing arrangements, etc., should encourage such behaviour and be 
devised in line with information on the relative cost-effectiveness of alternative 
treatment strategies. In other words, the reimbursement rates in a DRG-type 
payment system should reflect the costs of applying the most efficient treatment 
alternative. If the relative rates do not reflect most efficient solutions, hospital 
managers cannot be expected to behave efficiently. 
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There are a number of impediments for efficient behaviour of managers and 
professionals within the hospital, and the use of cost-effectiveness information in 
particular. One is the compartmentalization of specific budgets. Most health care 
institution managers face tight budgets and will be mostly interested in cost 
consequences, and only in direct costs rather than indirect costs, and only in so far 
as resources saved can be quickly utilized or costed in another area. So in practice 
the selected course of action will often differ from what is efficient from a societal 
viewpoint. Decision-makers at decentralized levels often complain about this lack 
of stimuli towards efficiency and may loose their interest in economic appraisal 
studies. 
Another hurdle is the fact that sometimes budgets are not really closed and that 
there are options to shift costs to other budgets, which precludes a full trade-off 
between costs and benefits. This is for instance the case in the UK and the 
Netherlands, where hospitals sometimes have the opportunity to offload some of 
their prescribing costs on the primary care sector. Furthermore, pharmaceutical 
companies often heavily discount their medicines to hospitals to make them 
attractive to formulary committees in the hope that their use is also extended to 
primary care settings. From these examples it is evident, that a broad view, passing 
the borders of institutions and health care sectors, is required. Compartmentaliza- 
tion of budgets within institutions should be minimized and shifting resources 
across departmental budgets on the basis of cost-effectiveness claims should be 
made possible. 
In the U.S., managed care organizations, which are well placed to initiate and use 
economic appraisals, have not yet established a good track record of activities in 
this field [9]. Their dominant perspective appears to be cost-containment rather 
than efficiency. Also the way in which one attempts to increase the efficiency of 
Medicaid programs is guided by cost-control considerations. For instance, prior 
authorization for the use of expensive drugs is now the primary method by which 
Medicaid programs control drug expenditure. The design and evaluation of such 
control mechanism suggest that consequences in terms of cost reduction are the 
major outcome-indicators to be considered [lo]. 
One may argue that a final problem for the use of the results of economic 
appraisal studies in actual decision-making is the potential ‘conflict of interest’, 
faced by the individual health care provider, who should treat his patient in the best 
possible way. Most doctors would agree now that they have a responsibility to all 
their potential patients, and not only to their individual presenting patients. 
Doctors have learned to consider opportunity costs and how to include economic 
arguments in their judgement regarding different treatments. Results of the multi- 
disciplinary prospective studies performed in the context of the Investigational 
Medicine Program in the Netherlands quickly find their way in medical protocols 
for new forms of treatment. 
In summary, we observe that economic appraisal as a method is still in an early 
phase of diffusion among actors involved in resource allocation at the regional 
level. The primary obstacle for further diffusion seems to be a lack of incentives to 
act in line with a societal perspective on cost-effectiveness. Another hurdle is 
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probably a lack of knowledge and experience in this field, which should be tackled 
by educational programs targeted at these regional actors. 
3. Linking research and policy making 
Drummond [ll] mentioned a number of ways to increase the relevance of 
economic appraisal results: 
l maintaining methodological standards; 
l producing economic evidence in a timely fashion; 
l increasing the local validity of study results; 
l increasing the decision-maker involvement in the study; 
l improving the dissemination of study results; 
l taking note of the availability of policy instruments; 
l recognizing the conflicts and incentives surrounding the study. 
Rather than addressing all these issues, we would like to select two important 
issues, to which we may be able to add further and provide illustrative examples. 
3.1. Interpretation of study results 
The first of these issues is the interpretation of results from an economic 
appraisal and the subsequent use in policy-making. A number of authors [12-141 
have commented on the use of cost-effectiveness league tables and pointed to the 
problems associated with their use in policy-making. This has led to a recommenda- 
tion to policy-makers not to use cost-effectiveness estimates in a mechanistic 
fashion and to carefully investigate whether the reported cost-effectiveness ratio is 
relevant to their policy context. Moreover, very little is actually known about how 
policy-makers use information on cost-effectiveness. It would be particularly 
difficult for them to select the most cost-effective version of a health care program 
when a choice has to be made between various alternatives which differ in intensity 
or scale. The interpretation of differential cost-effectiveness ratios becomes burden- 
some in such cases. 
Let us illustrate this with two examples, the first of which actually led to a clear 
policy-decision. This example is drawn from a study from De Koning et al. [15] in 
Rotterdam, who reported on the cost-effectiveness ratio of introducing breast 
cancer screening in the Netherlands. For the calculation of the costs, it was 
assumed that the screening program would have started in 1990 and that it would 
end in 2017. The costs and effects of mass screening in this period, occurring after 
2017, are computed until all women, who may have benefited from the screening 
program, will have died. Table 2 provides the results of the study for different 
screening policies, using different age groups and different screening intervals. The 
2-yearly screening program for women aged 50-70 is predicted to detect 26% of all 
diagnosed breast cancers in the population. The table shows that the screening 
option for age group 50-65 with an invitation interval of 3 years is most 
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Table 2 
Effects on mortality, costs, cost-effectiveness and cost-utility for different breast cancer screening policies 
( 1990%2017) in The Netherlands 
Age group and screening interval 
50-70; 
2 years 
40-70; 
2 years 
50-70; 50-75; 50-65; 
1.3 years 2 years 3 years 
Difference in costs 233 346 328 265 133 
Breast cancer deaths prevented 6000 6115 6780 6790 3770 
Life-years gained 61 000 64 000 70 000 64 500 41000 
Quality-adjusted life years gained 57 500 59 500” 66 000 59 500 39 300 
(QALYs) 
Cost (US%) life-year gained (CE per 3825 5385 4670 4100 3235 
ratio) 
Cost (US?%) QALY per 4050 5815” 5000 4450 3400 
Costs in millions USS (unless stated) with 5% discount rate; cost amounts are expected differences 
between situation with and without screening (prices 1990); source: De Koning et al. [15]. 
* No age-specific data for treating women < 50 years. 
cost-effective, followed by the option for the age group 50-70 and a 2-year interval. 
These cost-effectiveness ratio’s relate to the reference situation without systematic 
screening. An infinite number of options and associated cost-effectiveness ratios 
could have been reported, and without a clear decision-rule it would be very 
difficult to select the best option from a policy perspective. In this case, the initial 
preference by field experts for the age group 50-70 and a 2-year invitation scheme 
settled the matter and could be defended on the basis of the results. The cost-effec- 
tiveness ratio as compared to a situation without screening is only slightly higher 
than in the 50-65 years/3-year interval case and the number of QALYs gained in 
the former case is, of course, much higher than in the latter case. Note that in this 
case it would have been necessary to define rather precisely the cut-off point for 
incremental cost-effectiveness to arrive at the same conclusion. The obvious lesson 
from this case is that policy-makers want to act on more detailed information than 
only a reported incremental cost-effectiveness ratio. 
Another example comes from a recently completed study by Michel [16] on the 
relative cost-effectiveness of various diagnostic strategies for patients with suspected 
pulmonary embolism in the Netherlands. Five different diagnostic tests with various 
cut-off points and a clinical decision-rule were considered in combination, which led 
to 11 605 alternative diagnostic strategies. Relative costs and effects were calculated 
for each of these strategies, and 11 563 of these were identified as inferior, meaning 
that they produced less benefits and more costs than an alternative strategy. The 
remaining 42 superior strategies were compared with a strategy recommended by a 
1992 Dutch consensus meeting. In 12 of the remaining 42 superior strategies less 
investments than in the consensus strategy yielded more QALYs, as shown in Fig. 
1. Again, it is difficult to draw a firm conclusion here. One may say that the 
strategies on top of the small notches of the line are the most appealing strategies, 
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like numbers 3, 8 and 12. They combine relatively few costs with many QALYs in 
comparison with the neighbouring strategies. Again, a fairly sophisticated decision- 
rule is necessary to arrive at a conclusion and an educated policy-maker would like 
to see the position of all dominant strategies rather than the conclusion that 
strategy 13 is the preferred choice if a marginal cost-effectiveness ratio of less than 
NLG 55 000 per QALY in all steps from strategies 2- 13 is deemed acceptable. 
3.2. Extrapolation of study results 
As resources and even more so expertise to conduct economic appraisal studies 
are scarce, it is obviously not possible to perform a specific study for each local 
setting. However, policy-makers would prefer information on the cost-effectiveness 
of various strategies, which is as much as possible adopted to their policy problem. 
In the draft version of the most recent Australian guidelines [17], it is stated in the 
preface, that ‘the results of overseas trials of sufficient quality are a reasonable basis 
for economic evaluations relevant to the Australian health care system. However, 
an economic evaluation performed overseas will often not be suitable because of 
major differences in unit costs, the patterns of resource use and the way in which 
health care is funded. Companies are therefore encouraged to submit an evaluation 
which is relevant to local conditions’. These guidelines further specify how mod- 
elling may help in extrapolating from clinical trials: 
l to link the surrogate outcomes measured in the trials to final outcomes; 
l to extrapolate the outcomes measured beyond the duration of the trials and 
duration of therapy within the trials to the likely duration of use; 
l to examine the impact of differences between the eligibility criteria and settings 
of the trials and those that pertain to patients likely to obtain the drug on the 
Pharmaceutical Benefit Scheme; - 
0,04 - 
0,03 -- 
0,02 -- 
0,Ol -- 
-200 -100 
Additional costs 
n I 
0 
Fig. 1. The non-decreasing function of QALYs relative to costs for the 12 ‘superior’ diagnostic strategies, 
compared to the consensus strategy. Source: Michel [16]. 
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l to modify resource use patterns measured in the trial to reflect more closely 
those in Australia; 
l to include any relevant differences in resource consumption not measured in the 
trials and to exclude ‘protocol derived’ resource consumption. 
The fourth of these suggested applications of modelling relates directly to 
extrapolation across countries, but the others may also contain country specific 
elements. For instance, extrapolating from the surrogate outcome reduced choles- 
terol level to the final outcome life years gained as a consequence of reduced 
incidence of cardiovascular disease may be done differently in Europe than in the 
U.S., using country specific epidemiological databases and country specific mortal- 
ity statistics. 
Given the clear need of policy-makers to have at their disposal technology 
assessments relevant to their specific policy context, it is surprising that there has 
been little discussion in the literature on the methodology of extrapolation. One of 
the exceptions is a paper by Drummond et al. [ 181, who explored these issues in the 
context of the evaluation of a new drug to prevent gastric ulcers in people 
experiencing symptoms during long-term non-steroidal anti-inflammatory drug use. 
This particular evaluation was performed in Belgium, France, the UK and the USA 
using identical methodology. Their conclusion was that extrapolation of results 
from country to country is greatly facilitated if the economic evaluation is struc- 
tured in a decision tree format. This enables data particular to the individual 
countries to be introduced in order to examine the impact on estimates of costs and 
benefits. In this case, despite great variation in the costs of outpatient care and 
inpatient care in the various countries, the overall expected costs of 3 months 
prophylaxis were found to be remarkably similar in the four countries studied. 
A contrasting result was found by Van Hout et al. [19], who compared the 
differences in costs for the heart transplant programs in the UK and the Nether- 
lands. They found that the variable costs during the first year of treatment 
including transplantation in the Netherlands exceeded those in the UK by more 
than 70%, when corrected for general differences in purchasing power in both 
countries (Table 3). 
And finally, Van Ineveld et al. [20] have shown that it may be quite misleading 
to extrapolate in a straightforward way from one study performed in a particular 
country to other countries. They explored in detail the differences in cost-effective- 
ness of a national program on breast cancer screening in Spain, France, the UK 
and the Netherlands. It was found necessary to use country specific data on 
incidence, mortality, demography, screening organization and price levels in health 
care rather than performing a simple extrapolation of the cost-effectiveness ratio 
found for the Netherlands and the UK to the Southern European countries. Using 
their more sophisticated extrapolation technique they found that cost-effectiveness 
ratios in the UK, France, and Spain were 0.9, 2.7 and 4.6 times as large as the 
cost-effectiveness ratio for the Netherlands (Table 4). So a simple recommendation, 
based on the Dutch study, to implement nationwide screening in all European 
countries cannot be sustained. 
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Table 3 
Costs during the first year after transplantation: the UK and The Netherlands 
UK (1984 USS ppp) The Netherlands (1987 US$ ppp) 
Volume Price costs Volume Price costs 
Donor operation I 1691 1691 I 1738 1738 
Transplant operation I 902 902 1 4165 4165 
Inpatient days 47 224 10511 44 235 10 247 
Outpatient visits 18 24 435 27 57 1556 
X-rays 72 9 627 35 23 803 
Biopsies 13 47 600 15 367 5512 
Catheterisations 0.37 142 53 2 798 1348 
ECGs 34 9 329 44 20 889 
T-cells assays 28 27 733 42 13 555 
Cycle-assays 34 9 329 48 13 635 
Physiotherapy (h) 12 13 151 11 33 376 
Gates bloodpool scans I 9 9 3 111 308 
Drugs 9702 12702 
Laboratory tests 3529 7485 
Other services 813 4089 
Total 30413 51 169 
Source: Van Hout et al. 1191. 
In conclusion, we suggest that studies should be designed, carried out and 
reported in such a way that extrapolation to other settings and across national 
borders is facilitated. In this respect it is helpful to clearly structure the analysis and 
provide the necessary details which may require modification in an extrapolation- 
exercise. For instance, regarding costing it is necessary to report on resource use by 
presenting natural units and unit prices separately. Increasingly international 
clinical trials incorporating prospective economic appraisal studies are being per- 
formed in such a way that the potential of drawing valid conclusions for the various 
countries participating in such a trial is maximized. We think that the ‘art of 
extrapolation’ will become a research area of its own with its specific methodology 
and informatics like the OHE and NHSjCRD data bases for economic appraisal 
studies in the UK. 
Table 4 
Cost-effectiveness of mass screening for breast cancer (1990-2017) 
Netherlands UK 
Uniform screening systema 2120 2000 
National screening systemb 2120 1800 
% of GDP to health care 8.1 6.1 
Discount rate, 5%; prices 1990, pounds sterling. 
“Vertical, specialized organization of screening (Dutch model). 
bHorizontal, non-specialized organization in France and Spain. 
France Spain 
3400 4900 
5800 9700 
8.9 6.6 
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4. A glance into the future 
Although there is much talk about economic evaluation and medical technology 
assessment and their relevance for health policy, still little ground has been covered 
in actual practice. A recent OTA-report [21] mentions only Sweden out of a set of 
eight countries as showing a significant impact of technology assessment on health 
policy making. The systematic approach of the Dutch Health Insurance Executive 
Board to use economic appraisal for deciding on the health insurance package, and 
the requirement to submit economic appraisal studies for deciding on listing of 
drugs in Australia, are two examples of applications of economic evaluation, which 
may diffuse further across countries. For this to happen results of economic studies 
should become available in a timely fashion and be relevant to the policy context. 
An important hurdle that has to be taken is the lack of incentives to use results of 
economic evaluation studies, especially when central government regulation will 
become less important and the need to support these policies with evidence from 
economic appraisal studies will be reduced. When resource allocating authority is 
decentralized, regional and local parties in health care will require similar informa- 
tion and indeed Henshall and Drummond [22] argue that competitive forces may 
encourage individual parties to consider cost-effectiveness information. However, 
individual insurers or health care organizations may find it difficult to finance 
economic appraisal studies producing results of a more general value than only for 
one particular insurer or health care organization. A free rider problem emerges 
when such information is also freely available to others. If the information is clearly 
marked as having a commercial value, there will be obvious problems with the 
dissemination of such information. Devising and enforcing the right incentives to 
policy-makers at the regional and local level is vital to the further diffusion and 
greater use of economic appraisal studies. 
At the level of the European Union, formal rules in pharmaceutical research and 
in procedures for registration have been in place since 1965. With respect to 
registration there is now a central and a multistage procedure, but these do not 
extend to economic considerations. With respect to central registration a trend 
towards a multiple step procedure can be observed: a quick registration on a 
conditional basis, resubmission of information at specified intervals to get re-regis- 
tration and careful monitoring of developments in terms of effectiveness and safety. 
Maybe we will see reimbursement decisions follow this iterative process: a quick 
reimbursement and listing decision on the basis of cost-efficiency, preferably on the 
basis of a piggy-back study, monitoring of cost-effectiveness in actual practice by 
assessing real effectiveness, the diffusion of the drug across new or broadened 
indication groups and actual compliance of patients, and resubmission of cost-effec- 
tiveness data after a certain period of time using evidence from outcomes research, 
compliance studies, naturalistic economic studies, etc. 
Finally, we observed a large variation in policy instruments used in various 
sectors within health care and different ways of using cost-effectiveness information. 
Increasing international cooperation, both in research and policy, will probably 
lead to some convergence of policy approaches around a few of the policy trends 
mentioned above. 
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